Jessica Carrion, PTA | |
Via 16 Villa Fontana, Jr 8, Carolina, PR 00983 | |
(939) 339-6102 | |
Not Available |
Full Name | Jessica Carrion |
---|---|
Gender | Female |
Speciality | Physical Therapy Assistant |
Location | Via 16 Villa Fontana, Carolina, Puerto Rico |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255945598 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Jessica Carrion, PTA Calle Rufina Castillo, 507, Las Piedras, PR 00771 Ph: (787) 217-7404 | Jessica Carrion, PTA Via 16 Villa Fontana, Jr 8, Carolina, PR 00983 Ph: (939) 339-6102 |
News Archive
Orexo AB and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in October 2007.
HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in San Francisco, researchers will present findings that showed that in rats, the use of magnesium sulfate significantly reduced the neonatal brain injury associated with maternal inflammation or maternal infection.
› Verified 7 days ago